



JAGSONPAL PHARMACEUTICALS LIMITED
 Regd. Office: T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
 Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900
 CIN No. L74899DL1978PLC009181

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31.12.2019

Particulars	Standalone						Rs. in Lakh
	Quarter Ended			• Nine Month Ended			12 Months
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Income from operations							
a Gross Sales/Revenue from Operations	4201.04	4180.59	4189.45	12905.03	12842.34	16682.56	
b Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00	
Total Income from operations	4201.04	4180.59	4189.45	12905.03	12842.34	16682.56	
2 Other Income	65.08	44.38	27.86	176.58	54.95	142.90	
3 Total Income [1+2]	4266.12	4224.97	4217.31	13081.61	12897.29	16825.46	
4 Expenses							
a Cost of materials consumed	1244.12	756.22	1290.77	3173.47	3132.32	3878.66	
b Purchases of stock-in-trade	535.02	461.38	399.80	1471.23	924.69	1464.08	
c Changes in inventories of finished goods, work in progress and Stock in trade	-380.60	371.10	106.07	191.61	1840.63	1941.82	
d Employee benefits expenses	1461.64	1246.90	1274.04	4023.05	3601.22	4661.10	
e Finance Cost	10.12	14.81	10.42	36.70	47.24	74.55	
f Depreciation and amortisation expense	25.95	26.72	23.06	81.28	73.45	101.58	
g Other expenses	1084.46	1094.21	898.72	3314.77	2751.16	3803.39	
Total expenses	3980.71	3971.34	4002.88	12292.11	12370.71	15925.18	
5 Profit before exceptional items and taxes (3-4)	285.41	253.63	214.43	789.50	526.58	900.28	
6 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	
7 Profit before tax [5-6]	285.41	253.63	214.43	789.50	526.58	900.28	
8 Tax expense	57.09	50.72	40.00	157.90	102.43	178.67	
9 Net Profit for the period [7-8]	228.32	202.91	174.43	631.60	424.15	721.61	
10 Other Comprehensive Income							
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	
11 Total Other Comprehensive Income [A(i) + A(ii)]	0.00	0.00	0.00	0.00	0.00	0.00	
12 Total Comprehensive Income [9+11]	228.32	202.91	174.43	631.60	424.15	721.61	
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90	
14 Earnings Per Share of Rs 5/- each (before and after extraordinary items)							
a. Basic (Rs.)	0.87	0.77	0.67	2.41	1.62	2.75	
b. Diluted (Rs.)	0.87	0.77	0.67	2.41	1.62	2.75	

Notes :

- The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 13, 2020. The results have been subjected to Unaudited review by statutory Auditors of the Company.
- In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
- The revenue for the quarter ended 31-12-2019, is reported net of GST.
- Provision for taxation includes provision for current tax.

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director

DIN No 00059492

Place : New Delhi

Date : 13-02-2020

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953